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Abstract
Background: The standardized uptake value (SUV) is the nearly exclusive means for quantitative evaluation of
clinical [18F-]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) whole body investigations.
However, the SUV methodology has well-known shortcomings. In this context, it has been recognized that at least
part of the problems can be eliminated if tumor SUV is normalized to the SUV of a reference region in the liver
(tumor-to-liver [TLR] ratio ). In recent publications, we have systematically investigated the tumor-to-blood SUV ratio
(SUR) for normalization of tumor SUVs which in our view offers principal advantages in comparison to TLR. The aim of
this study was a comprehensive comparison of TLR and SUR in terms of quantification of tumor lesions.
Methods: 18F-FDG PET/CT was performed in 424 patients (557 scans) with different tumor entities prior to
radio(chemo)therapy. In the PET images, SUVmax of the primary tumor was determined. SUVliver was calculated in the
inferior right lobe of the liver. SUVblood was determined by manually delineating the aorta in the low-dose CT. TLR and
SUR were computed and scan time corrected to 60 min p.i. (TLRtc and SURtc). Correlation analysis was performed for
SUVliver vs. SUVblood, TLR vs. SUR, SUVliver/SUVblood vs. SUVblood, SURtc/TLR vs. SURtc, and SURtc/TLRtc vs. SURtc.
Variability of the respective ratios was assessed via histogram analysis. The prognostic value of TLR and TLRtc for
distant metastases-free survival (DM) was investigated with univariate Cox regression in a homogeneous subgroup
(N = 130) and compared to previously published results for SUV and SURtc.
Results: Correlation analysis revealed a linear correlation of SUVliver vs. SUVblood (R2 = 0.83) and of TLR vs. SURtc
(R2 = 0.92). The SUVliver/SUVblood ratio (mean ± s.d.) was 1.47 ± 0.18. For the SURtc/TLR ratio, we obtained 1.14 ±
0.21 and for the SURtc/TLRtc ratio 1.38 ± 0.17. Survival analysis revealed TLR and TLRtc as significant prognostic factors
for DM (hazard ratio [HR] = 3.3 and HR = 3, respectively). Both hazard ratios are lower than that of SURtc (HR = 4.1)
although this reduction does not reach statistical significance for the given limited group size. HRs of TLR and SURtc
are both significantly higher than HR of SUV (HR = 2.2).
Conclusions: Suitability of the liver as surrogate of arterial tracer supply for SUV normalization via TLR computation is
limited. Further studies in sufficiently large patient groups are required to better characterize the relative performance
of SUV, TLR, and SUR in different settings.
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Background
The standardized uptake value (SUV) currently is
the nearly exclusive means for quantitative evaluation
of clinical [18F]fluorodeoxyglucose (18F-FDG) positron
emission tomography (PET) whole-body investigations.
However, the SUV methodology has well-known short-
comings such as uptake time dependence of the SUV,
unsatisfactory test/retest stability, susceptibility to errors
in scanner calibration etc. [1–6] all of which adversely
affect the reliability of the SUV as a surrogate of
the metabolic rate of FDG (and ultimately of glucose
consumption).
In this context, it has been recognized repeatedly that
at least part of the mentioned problems can be reduced
or eliminated if tumor SUV is normalized to the SUV of
a suitable reference region [7]. Especially, the liver has
drawn considerable attention as a useful reference region
since the liver does not irreversibly trap the FDG and
maintains a roughly constant SUV level during the time
window relevant for whole-body FDG PET (about 60–
120 min p.i.) [8–13]. In fact, the liver is the only reference
region which so far has been studied and used extensively.
Using the tumor-to-liver-ratio (TLR) obviously removes
some of the SUV limitations, i.e. possible inaccuracies
regarding actually injected dose, scanner calibration, and
patient weight index (either actual body weight, lean body
mass [14], or body surface area [15]).
However, TLR exhibits an uptake time dependence
comparable to that of tissue SUV itself (without a gener-
ally accepted means of quantitatively correcting for this
effect in either case). Possibly more important, liver SUV
(SUVliver) will exhibit an inter-individually (and possi-
bly also intra-individually in case of aggressive treatment
such as chemotherapy) variable relation to the given arte-
rial tracer supply. On the other hand, it is the latter—
expressed in SUV units (SUVblood)—which determines a
given lesion’s observed SUV. Usefulness of the liver as a
reference might be further compromised in the presence
of liver disease or pharmacological intervention [16, 17].
Last but not least, depending on the investigation, the liver
might simply not be routinely included in the field of view
of the PET scan (e.g. at the participating sites in head and
neck investigation, the liver is not always included in the
FOV while a sufficiently large part of the aorta still is). For
all these reasons, the liver cannot be considered an ideal
reference region.
In recent publications, we have systematically investi-
gated the tumor-to-blood SUV ratio (SUR) for normal-
ization of tissue SUVs which in our view offers principal
advantages in comparison to TLR. For one, the SUR
approach by definition eliminates the influence of the per-
sisting residual variability of SUVblood on lesion SUV and
ensures that SUR is superior to lesion SUV itself as a
surrogate parameter of the metabolic rate of FDG [18].
Additionally, we were able to show that it is possible to
reliably correct SUR for variations of the 18F-FDG uptake
period under rather general and empirical well-fulfilled
assumptions regarding the shape of the arterial input
function (AIF) [19]. These advantageous properties of the
SUR can be ultimately traced back to the empirical fact,
that the AIF after FDG bolus injection exhibits an essen-
tially invariant shape, following a simple inverse power
law starting immediately after the bolus phase. Finally, we
found strong evidence in a survival analysis of 130 patients
with esophageal carcinoma that the superior properties
of SUR also translate into a higher prognostic value [20].
While there is thus rather strong theoretical and empiri-
cal evidence for the superiority of SUR over SUV, it is so
far an open question how performance of SUR compares
to that of TLR.
The primary aim of the present investigation, therefore,
was accurate determination of the degree of correlation
between TLR and SUR. A secondary goal was to perform
a first direct comparison of the performance of TLR and
SUR as predictor of therapy outcome. For this purpose,




In this retrospective study, 424 patients (358 men, 66
women) with mean age (range) 63 (37–85) years and
different tumor entities (head and neck cancer N = 36
(HNC), non small cell lung cancer N = 178 (NSCLC),
esophageal carcinoma N = 210 (EC)) were included. This
patient group incorporates 130 patients with esophageal
carcinoma treated with definitive radio(chemo)therapy
previously investigated in the already mentioned study
by Bütof et al. [20]. This subgroup is utilized in the
present study for comparison of the prognostic value
of TLR and SUR. In 84 out of 424 patients, two PET
scans were performed at different days, where the first
scan was before radio(chemo)therapy and the second scan
afterwards. Time between first and second scan was on
average 39.1 days (range 10–76). These data were included
to study the intra-subject variability. In 49 out of 424
patients, dual time-point measurements were performed,
and the respective late scans were included to extend the
range of covered uptake times (up to 120min). Altogether,
557 18F-FDG PET/CT scans were performed at Univer-
sity Hospital, Technische Universität Dresden (Site A) and
at the University Hospital, Otto-von-Guericke University
Magdeburg (Site B). Only scans where the liver as well as
the aorta was in the FOV were included. Scan characteris-
tics are summarized in Table 1. All scans besides the above
mentioned were performed before radio(chemo)therapy
and/or surgery. All patients had fasted for at least 6 h prior
to 18F-FDG injection. The serum glucose concentration
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Table 1 Scan characteristics
Site A Site B
Number of patients 264 160
Number of scans 363 194
Scanner type Biograph 16 PET/CTa Biograph mCT 64a
Dosage (MBq) 336 ± 38 234 ± 12







OSEM 6i/4s PSF+TOF 2i/21s
aSiemens Medical Solutions Inc., Knoxville, TN, USA
measured prior to injection was 5.9 mmol/L on average
(range 3.3–10.7).
Image analysis
ROI definition and ROI analyses were performed using
the ROVER software, version 2.1.20 (ABX, Radeberg,
Germany). Here and in the following, “ROI” is used syn-
onymously with “VOI” for denoting a three-dimensional
volume of interest.
The metabolically active part of the primary tumor was
delineated by an automatic algorithm based on adaptive
thresholding taking the local background into account
[21]. The result of the automatic delineationwas inspected
visually by an experienced observer (one observer at each
site) and corrected manually in case of obvious segmen-
tation failure. For the resulting ROIs, SUVmax was com-
puted. In the following, the index “max” is omitted, since
only the maximum of lesion SUV and derived quantities
(TLR, SUR) was considered in the evaluation.
The arterial blood SUV was determined by defining a
roughly cylindrical aorta ROI in the attenuation CT data
which than was transferred to the PET data. To exclude
partial volume effects, a concentric safety margin was
used in the transaxial planes, centering the ROI in the
aorta. Planes showing high tracer uptake close to the aorta
(pathological or otherwise) were excluded. The aorta ROI
was positioned in the descending aorta, and the minimum
volume was 5 ml. For the determination of the SUVliver, a
spherical 3D ROI with a diameter of approximately 3 cm
(14 ml) was placed on the normal inferior right lobe of
the liver. TLR (SUR) was computed as ratio of maximum
lesion SUV and mean SUV of the liver (aorta) ROI. In
the following, we omit the index “mean” for liver (aorta)
SUV. Scan time corrected SUR values were computed as
described in [19]:
SURtc = T0T × (SUR − Vr) + Vr






where T is the actual scan time p.i. and T0 is the cho-
sen standard scan time to which the SURs are normalized
(60 min in the present work). Vr = 0.53 ml/ml is an
estimate of the apparent volume of distribution, corre-
sponding to the y-axis intercept of a Patlak plot, previously
derived in dynamic investigations [22]. Note, that for not
too small SUR values, the influence of Vr is small and
might be neglected, simplifying the correction formula to
SURtc = T0T × SUR.
As our previous work [20] demonstrates, the scan-time
correction distinctly improves the prognostic value of the
SUR, and it is thus the scan-time corrected value SURtc
which should be compared against TLR. Of course, TLR
is scan-time dependent as well but usually no attempt is
made to correct for this effect, so the primarily relevant
comparison is that between SURtc and this (scan time
uncorrected) TLR. But, for completeness sake, we also
compared SURtc with a scan-time-corrected TLR as fol-
lows. For scan time correction of TLR, we note that the
SUVliver is nearly time-independent in the relevant time
window (≈60−120 min p.i.) so that the fractional change
of TLR over time is essentially identical to the correspond-
ing change of lesion SUV. In [19], we have demonstrated
that scan time correction of lesion SUV is possible—
although somewhat less accurate than for SUR—but in
principle requires knowledge of SUVblood. However, an
approximate correction is possible without this knowl-
edge. When using the TLR approach instead of SUR (i.e.
in absence of SUVblood determination) this approximation
would be the only feasible approach which we have thus







where b = 0.313 is a parameter describing the shape and
decrease of the arterial input function over time (see [19]
for details).
Statistical analysis
Inter-subject variability of SUVblood and SUVliver was ana-
lyzed in the whole patient group where for patients with
two PET scans only the first scan was used (N = 424).
Inter-subject variability was assessed as standard devia-
tion (SD) of the distribution of the respective SUV. Intra-
subject variability of SUVblood and SUVliver was analyzed
in the subgroup of 84 patients that received two scans on
separate days. It was assessed as SD of the distribution of
SUV (= paired difference of the respective SUV in the
second and first scan). Inter- and intra-subject variabilities
were compared using a two-sided F test of the correspond-
ing variances (squared SDs) testing the null hypothesis
that they are equal.
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Linear correlation analysis of liver vs. blood SUV and
of TLR vs. SURtc (N = 557), respectively, was performed
and visualized through scatterplots. Linear correlation
analysis was also performed for LBR vs. SUVblood as
well as for SURtc/TLR and SURtc/TLRtc, respectively, vs.
SURtc. Variability of the respective ratios was assessed
via histogram analysis and quantified by mean ± SD and
90 % confidence interval (CI).
Survival analysis was performed in the patient group
already analyzed in [20] where the prognostic value of
several PET parameters and of clinically relevant param-
eters for overall survival, locoregional tumor control,
and distant metastases-free survival (DM) was investi-
gated. In the present study, we investigate the prognostic
value of TLR and TLRtc for DM (for which the largest
effect size was found in our previous study) using uni-
variate Cox regression. For comparison, we also show
the already published results for SUV and SURtc. Haz-
ard ratios were compared using the bootstrap method
(random re-sampling with replacement; 105 samples) to
determine the statistical distribution of (HR1 − HR2)
from which the relevant P value than was derived.
Statistical significance was assumed if P < 0.05. Sta-
tistical analysis was performed with the R language
and environment for statistical computing [23] version
3.1.2.
Compliance with ethical standards
All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of
the institutional and/or national research committee and
with the 1964 Helsinki declaration and its later amend-
ments or comparable ethical standards. Informed consent
was obtained from all individual participants included in
the study.
Results
Voxel intensities of blood and liver ROIs exhibited com-
parable average standard devitations of 10.7 % (liver) and
11.3 % (blood), respectively, corresponding to standard
errors of the mean values of 1.36 % (scan start p.i. 60–
75 min: 1.22 %, >75 min 1.49 %) (liver) and 1.43 %
(60–75 min 1.23 %, >75 min 1.60 %) (blood), respectively.
The mean values of SUVblood and SUVliver across all
424 investigated patients were 1.79 ± 0.36 and 2.56 ±
0.55, respectively. Themean intra-individual paired differ-
ences, SUVblood and SUVliver, in 84 patients receiving
two PET scans on different days were 0.05 ± 0.32 and
0.24± 0.42, respectively. This demonstrates that the inter-
and intra-subject variability (i.e. the respective standard
deviations) of both SUVs are of very similar magnitude
(although the small positive difference between the inter-
and intra-subject SUVliver variability actually reaches sta-
tistical significance [P = 0.003]).
Correlation analysis revealed a pronounced linear cor-
relation of SUVliver and SUVblood (R2 = 0.83) and of
TLR and SURtc (R2 = 0.92). Corresponding scatterplots
are shown in Fig. 1. There were no notable differences
between investigating sites, tumor entities, or tumor size
(Table 2). For LBR, we obtained 1.47 ± 0.18 (90 % CI 1.2–
1.78). Corresponding scatterplot and histogram are shown
in Fig. 2. For the SURtc/TLR ratio, we obtained 1.14± 0.21
(90 % CI 0.82–1.48) and for the SURtc/TLRtc ratio 1.38 ±
0.17 (90 % CI 1.12–1.65). Corresponding scatterplots and
histograms are shown in Fig. 3. Obviously, time correc-
tion of TLR reduces the fractional variability of the ratio
(from about 18 to 12 %). For all ratios, there was no notable
difference between investigating sites, tumor entities, or
tumor size (Table 3).
Survival analysis (N = 130) revealed TLR and TLRtc as
significant prognostic factors for DM without being sig-
nificantly different from each other (HR = 3.3 and HR =
3, respectively). These hazard ratios are to be compared
with the previously reported results from this patient
group [20] for SUV (HR = 2.2) and SURtc (HR = 4.1).
Further details can be found in Table 4. Corresponding
Kaplan-Meier curves are shown in Fig. 4.
According to bootstrap resampling, HRs of TLR and
SURtc were both significantly higher than the HR of SUV
(P = 0.019 and P = 0.048, respectively) while the HR
difference between TLRtc and SUV was not significant
(P = 0.17). The HR difference between SUR and TLR or
TLRtc was also not significant (P = 0.31 or P = 0.16).
Discussion
Figure 1a demonstrates a pronounced but far from per-
fect linear correlation between SUVliver and SUVblood.
Indeed, a stronger correlation of both quantities might be
expected since in any single investigation, tracer uptake
at a given time point in any given target region (the
liver included) is proportional to the overall scale of the
AIF and, consequently, to its value at the chosen time
point. Thus, in view of the fact that the AIF exhibits
an essentially invariant shape across different investiga-
tions [18, 19] and presuming the metabolic state of the
liver could be considered sufficiently similar with respect
to uptake and release of FDG across different investiga-
tions/patients, a near-perfect linear correlation (actually,
a proportionality) would result in Fig. 1a, at least for suffi-
ciently standardized uptake time. However, this is not the
case.
Considering the possible explanations, it is easily veri-
fied that the deviations from a perfect straight line are not
a consequence of statistical errors due to the given sig-
nal to noise ratio of the corresponding ROI averages [24].
Systematic errors due to regionally variable accuracy of
attenuation or scatter correction, too, would not be able
to disturb the linear correlation to such an extent.
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a b
Fig. 1 a Correlation between SUVliver and SUVblood. b Correlation between TLR and SURtc. Black lines represent the least squares straight line fits to
the data. Red lines depict the 95 % CI
Excluding measurement-related effects, two obvious
possible explanations remain for the sizable deviations
from perfect linear correlation. First, the correlationmight
be adversely affected by differences in uptake time (color-
coded in the scatter plots) since the time activity curves in
liver and blood have different shapes and the LBR, thus, is
time-dependent (slowly increasing over time). It is obvi-
ous from the color-coding of the data points according to
uptake time in Figs. 1a and 2a that this effect at most is
responsible for a minor part of the scatter, driving LBR to
somewhat higher values at late times (which on average
correspond to lower SUVblood values, explaining the small
but significant negative correlation of LBR and SUVblood
in Fig. 2a).
The only remaining plausible explanation in our view is
to attribute the scatter to non-negligible inter- and intra-
individual quantitative differences of FDG kinetics in the
liver between different patients or scans.
Table 2 Correlation (R2) of SUVblood vs. SUVliver and TLR vs. SUR.
All correlations were significant ( P < 0.001)
Group Liver vs. blood TLR vs. SURtc
All 0.83 0.92
Site
Site A 0.8 0.92






Volume <10 ml 0.81 0.92
Volume ≥10 ml 0.85 0.91
Regarding the degree of intra-subject variability of
SUVliver and SUVblood separately, our results are in good
quantitative agreement with [4]. Our data furthermore
demonstrate that inter-subject variability of both quanti-
ties is very similar to the respective intra-subject variabil-
ity (although the difference reaches statistical significance
in case of the liver where inter-subject variability is slightly
larger than the intra-subject variability). We believe this
to be an important observation in itself; intra- and inter-
individual fluctuations of SUVliver and SUVblood do have
very similar magnitude.
While our data thus essentially confirm and augment
existing data regarding inter-scan variability of SUVliver
and SUVblood they, furthermore, provide to our knowl-
edge the first comprehensive investigation of the degree of
correlation between both quantities. Regarding utilization
of the liver as reference region for lesion SUV normaliza-
tion, our data demonstrate that the liver in fact cannot be
considered a highly accurate substitute for actual arterial
tracer supply; from the data shown in Fig. 2, we derive
an LBR of 1.47 ± 0.18 with a 90 % confidence interval of
1.2–1.78 whose limits differ by 48 %. These fluctuations
directly translate into spurious fluctuations of the derived
TLR values which would erroneously be interpreted as
being due to changes in lesion metabolism.
The magnitude of this effect is demonstrated in Fig. 1b
where TLR is compared to SURtc. While the correla-
tion coefficient is larger than that in Fig. 1a (ultimately a
consequence of the much higher dynamic range of SUR
and TLR in comparison to SUVblood and SUVliver), the
SURtc/TLR ratio in fact exhibits a fractional variability
that is distinctly higher than that of LBR (about 18 vs.
12 %) which also is apparent from a comparison of Fig. 2
and Fig. 3a, b. This increased variability is caused by
the fact that we use SURtc here, rather than the scan-
time uncorrected SUR for the reasons explained in the
introduction.
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Fig. 2 a Correlation between LBR and SUVblood. b Frequency distribution of LBR. a Black line represents the least squares straight line fit to the data.
Red lines depict the 95 % CI
Since uptake time correction of TLR is currently not
applied in clinical routine, one thus actually faces a vari-
ability of TLR in comparison to SURtc of 1.14 ± 0.21
(90 % CI 0.82–1.48) if actual scan times are as variable as
in our study group.
Also performing uptake time correction for TLR
approximates the situation where uptake times would be
strictly standardized (to 60 min in the present case). This
leads to the results shown in Fig. 3 which indeed demon-
strate a very similar mean and SD of the SURtc/TLRtc
a b
c d
Fig. 3 a Correlation between the SURtc/TLR ratio and SURtc. b Corresponding frequency distribution. c Correlation between the SURtc/TLRtc ratio
and SURtc. d Corresponding frequency distribution. Black lines represent the least squares straight line fits to the data. Red lines depict the 95 % CI
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Table 3 Variability of the ratios LBR, SURtc/TLR, and SURtc/TLRtc
LBR SURtc/TLR SURtc/TLRtc
Group Mean ± SD 90 % CI Mean ± SD 90 % CI Mean ± SD 90 % CI
All 1.47 ± 0.18 1.2–1.78 1.14 ± 0.21 0.82–1.48 1.38 ± 0.17 1.12–1.65
Site
Site A 1.45 ± 0.19 1.18–1.78 1.14 ± 0.22 0.82–1.55 1.37 ± 0.18 1.11–1.66
Site B 1.5 ± 0.18 1.23–1.79 1.15 ± 0.18 0.84–1.43 1.4 ± 0.16 1.15–1.64
Tumor entity
HNC 1.44 ± 0.15 1.2–1.66 1.16 ± 0.21 0.85–1.49 1.36 ± 0.14 1.12–1.61
NSCLC 1.49 ± 0.18 1.23–1.8 1.14 ± 0.18 0.82–1.43 1.39 ± 0.16 1.14–1.64
EC 1.45 ± 0.19 1.18–1.78 1.15 ± 0.23 0.81–1.57 1.37 ± 0.19 1.09–1.66
Tumor size
Volume <10 ml 1.48 ± 0.19 1.18–1.78 1.16 ± 0.23 0.8–1.58 1.4 ± 0.19 1.12–1.66
Volume ≥ 10 ml 1.46 ± 0.18 1.2–1.78 1.13 ± 0.19 0.83–1.42 1.36 ± 0.16 1.13–1.62
ratio in comparison to the LBR data in Fig. 2. This should
be expected if the scan-time correction performs well
since the time dependence of LBR itself is rather weak as
already discussed above. The bottom line here is that the
SURtc/TLR ratio exhibits variability which is at least as
large as that of LBR but will be substantially higher under
typical clinical conditions where uptake times can vary
considerably [25, 26].
Accepting our point of view that SURtc for principal rea-
sons should be considered to represent the best available
surrogate of lesion glucose consumption (since it uses the
“correct” way of normalizing directly to the actual arterial
tracer supply and accounts for time dependence of both;
lesion uptake and AIF) the stated variability of SURtc/TLR
represents a principal limitation of the TLR as a surrogate
of lesion glycolysis.
Of course, even if this conjecture is correct, the real
question is how TLR performs in comparison to SUV
and SUR regarding its prognostic value. In comparison to
SUV, it has been repeatedly shown [12, 13, 27] that TLR
is capable of improving the prognostic value of the PET
investigation. It thus is unquestionably a valuable concept.
On the other hand, themuchmore recently proposed SUR
has not yet seen wide-spread evaluation and a comparison
to TLR has been completely missing so far. We therefore
Table 4 Univariate Cox regression with respect to DM (N = 130
patients with esophageal carcinoma)
Parameter Risk HR 95 % CI P value
SUV >14 2.2 1.1–4.7 0.035
TLR >5.8 3.3 1.5–7.3 0.003
TLRtc >4.7 3 1.3–6.7 0.009
SURtc >5.3 4.1 1.5–10.7 0.004
Results for SUV and SURtc have been taken from our paper [20]
consider the results presented in Fig. 4 and Table 4 of spe-
cial interest. They clearly demonstrate that TLR as well
as SURtc are superior to SUV as predictors of DM in the
investigated patient group. Uptake time correction of TLR
(TLRtc) did not improve the prognostic value as described
by the hazard ratios in Table 4 in comparison to TLR. This
was an initially somewhat unexpected result since uptake
time correction reduces the deviations from a constant
SURtc/TLRtc ratio. This finding might indicate that in our
patient group the improved prognostic value of SURtc is
causedmainly by the beneficial influence of normalization
to SUVblood rather than by scan-time correction. How-
ever, further investigations will be necessary to clarify this
question.
The already previously reported that HR of SURtc is
distinctly higher than HR of TLR (HR[SURtc] = 4.1,
HR[TLR] = 3.3). In the given study group with its limited
group size, though, the increase of HR is not large enough
to reach statistical significance in the bootstrap resam-
pling analysis. This indicates that the principal advantages
of SURtc over TLR (consideration of actual arterial tracer
supply and accurate uptake time correction) are not deci-
sive at the given level of statistical accuracy available in our
study group. Nevertheless, we believe that the observed
very weak indication of superiority of SURtc over TLR
is a sufficient incentive to further investigate the relative
performance of TLR and SUR in other patient groups.
Personally, we believe it very likely that ultimate supe-
riority of SUR over TLR will be demonstrated since the
latter parameter does not allow to fully account for the
inter- and intra-individual variability of arterial tracer sup-
ply (and thus remains subject to spurious changes which
are unrelated to differences in lesion glycolysis). In any
case, both parameters are clearly superior to SUV and in
practical termsmight be viewed to some extent as comple-
mentary concepts (rather than competing ones) since the
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Fig. 4 Kaplan-Meier curves with respect to DM (N = 130 patients with esophageal carcinoma). Results for SUV and SURtc have been taken from our
paper [20]
blood pool (aorta) will frequently be covered in the FOV
even when the liver is not (or when the presence of liver
disease precludes use of the TLR approach).
Overall, it seems worthwhile and promising to fur-
ther investigate the relative performance of SUV, TLR,
and SUR in other patient groups with the ultimate goal
of deciding whether SUR can be considered as gener-
ally superior to SUV and TLR. If this turns out to be
true, it would constitute a strong incentive to use SUR
as a drop-in replacement for the current SUV and TLR
methodology (or at least as an attractive alternative to the
latter one) in clinical whole body FDG PET.
Conclusions
Suitability of the liver as a surrogate of arterial tracer sup-
ply for SUV normalization via TLR computation is limited
due to the less-than-perfect correlation between blood
and liver SUV, and the SUR approach remains attrac-
tive for principal as well as practical reasons. Regarding
their respective prognostic value, both, TLR and SUR
significantly outperformed SUV. Further studies in suffi-
ciently large patient groups are required to better charac-
terize the relative performance of SUV, TLR, and SUR in
different settings.
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